argenx (ARGX) vs Moderna (MRNA)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 7, 2026.
Summary
Moderna (MRNA) has outperformed argenx (ARGX) over the past year, gaining 612.0% versus a gain of 16.5%. Over five years, ARGX leads with a +216.2% price change compared with -40.0% for MRNA. Moderna is the larger company by market cap ($78.44 billion vs $57.74 billion), about 1.4 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ARGX | MRNA |
|---|---|---|
| Share price | $928.44 | $196.48 |
| Market cap | $57.74B | $78.44B |
| 1-day change | -0.22% | +4.81% |
| YTD return | +10.46% | +560.05% |
| 1-year return | +16.50% | +611.96% |
| 5-year return | +216.24% | -39.96% |
| P/E ratio (TTM) | 35.38 | — |
| Forward P/E | 26.74 | — |
| EPS (TTM) | $26.24 | $-7.98 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | — | $1.94B |
| Revenue growth (YoY) | — | -39.93% |
| Net income (latest FY) | $1.29B | $-2.82B |
| Gross margin | — | 55.35% |
| Operating margin | — | -158.13% |
| Net margin | — | -145.16% |
| 52-week high | $1,072.75 | $212.22 |
| 52-week low | $661.85 | $22.28 |
| Distance from 52-week high | -13.45% | -7.42% |
| Analyst consensus | buy | hold |
| Avg. price target upside | +27.12% | -38.42% |
| Average volume | 283.20K | 17.31M |
| Shares outstanding | 62.19M | 399.24M |
| Employees | 1,863 | 4,700 |
| Sector | Healthcare | Healthcare |
| Industry | Biotechnology | Biotechnology |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- MRNA has outperformed ARGX by 595.5 percentage points over the past year.
About argenx
ARGX stock →argenx SE, a commercial-stage biopharma company, develops various therapies for the treatment of autoimmune diseases in the United States, Japan, China, the Netherlands, and internationally. The company offers VYVGART for the treatment of gMG and immune thrombocytopenia (ITP), and VYVGART HYTRULO for the treatment of gMG and chronic inflammatory demyelinating polyneuropathy (CIDP).
Healthcare · Biotechnology · 1,863 employees
About Moderna
MRNA stock →Moderna, Inc., a biotechnology company, provides messenger RNA medicines in the United States, Europe, and internationally. The company's respiratory vaccines include spikevax, mNEXSPIKE, mRESVIA, COVID, RSV, seasonal influenza, combination, and pandemic influenza vaccine; latent vaccines comprise cytomegalovirus, epstein-barr virus, and human immunodeficiency virus vaccines; enteric viruses include norovirus; public health vaccines consist of Zika, Nipah, and Mpox vaccines; and bacterial diseases vaccines, such as lyme vaccines.
Healthcare · Biotechnology · 4,700 employees
ARGX vs MRNA FAQ
Which is bigger, argenx or Moderna?
Moderna (MRNA) is larger, with a market capitalization of $78.44B compared with $57.74B for argenx (ARGX).
Which stock has performed better over the past year, ARGX or MRNA?
MRNA returned +611.96% over the past 12 months, compared with +16.50% for ARGX (price return, excluding dividends). Past performance does not predict future results.
Are argenx and Moderna in the same industry?
Yes. Both are classified in the Biotechnology industry within the Healthcare sector.